Pre-made Caplacizumab benchmark antibody ( Nanobody, anti-VWF therapeutic antibody, Anti-F8VWF/VWD Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Caplacizumab biosimilar, Nanobody, Anti-VWF Antibody: Anti-F8VWF/VWD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Caplacizumab (INN; trade name Cablivi) is a bivalent single-domain antibody (VHH) designed for the treatment of thrombotic thrombocytopenic purpura and thrombosis.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-093-1mg	1mg	3090
GMP-Bios-ab-093-10mg	10mg	Inquiry
GMP-Bios-ab-093-100mg	100mg	Inquiry
GMP-Bios-ab-093-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Caplacizumab biosimilar, Nanobody, Anti-VWF Antibody: Anti-F8VWF/VWD therapeutic antibody
INN Name	Caplacizumab
Target	VWF
Format	Nanobody
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	na
VD LC	na
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	NFD
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2011
Year Recommended	2012
Companies	Ablynx
Conditions Approved	Thrombotic thrombocytopenic purpura
Conditions Active	na
Conditions Discontinued	Thrombosis
Development Tech	Nanobody Technology